HKBU-led research team develops novel antiviral targeted drug for nasopharyngeal cancer

(Hong Kong Baptist University) A research team led by Hong Kong Baptist University (HKBU) has developed a novel anti-Epstein-Barr virus (EBV) drug that can selectively disrupt a viral protein produced by EBV, leading to the shrinkage of tumors caused by the virus. It is the first known agent to successfully target the virus and disturb its latency in tumor cells in this way.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news